|Bid||157.20 x 800|
|Ask||157.32 x 800|
|Day's range||156.71 - 160.88|
|52-week range||81.79 - 170.51|
|Beta (5Y monthly)||1.33|
|PE ratio (TTM)||234.86|
|Earnings date||28 Oct 2020 - 02 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||184.17|
IQVIA™ (NYSE: IQV) today announced that its electronic Clinical Outcome Assessment (eCOA) solution, an advanced-study build and execution platform that optimizes real-time, direct-from-patient data collection, has been selected as the winner of the Fierce Innovation Awards – Life Sciences Edition 2020 in the Digital Health Solutions category. The Fierce Innovation Awards is a peer-reviewed awards program produced by Questex, the publisher of Fierce Biotech and Fierce Pharma.
IQVIA™ (NYSE: IQV) was recognized at the 18th Annual American Business Awards®, winning the Gold Stevie® Award for Technical Innovation of the Year. IQVIA also won a Silver Stevie Award for Most Innovative Company of the Year.
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.